Your session is about to expire
← Back to Search
Behavioral Intervention
Project nGage for HIV (nGage Trial)
N/A
Recruiting
Led By Alida Bouris, PhD
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
No Placebo-Only Group
Summary
This trial tests an intervention to help young Black sexual minority men aged 18-35 stay in care and lower viral levels.
Who is the study for?
This trial is for young Black sexual minority men aged 18-35 with HIV who speak English, own a personal cell phone, and have missed an HIV care visit in the past year. They must identify as cisgender men and agree to involve a non-romantic social support person in the intervention.
What is being tested?
Project nGage is being tested for its effectiveness in helping participants stay engaged in their HIV care and maintain viral suppression. It's a tailored approach that uses patients' social networks to support their treatment journey.
What are the potential side effects?
Since Project nGage is a behavioral intervention leveraging social support rather than medication, it may not have typical medical side effects but could impact interpersonal dynamics within the participant's social network.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Missed Visit Proportion
Viral Suppression
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Project nGage ConditionExperimental Treatment1 Intervention
The Project nGage condition will be delivered by trained Intervention Case Managers to n=300 men (referred to as Index men) and their Support Confidant (SC).
The Project nGage intervention consists of (1) selection and invitation of a SC, (2) a face-to-face intervention between the Intervention Case Manager and the Index and SC, and (3) quarterly interactive mini-booster sessions delivered to the Index and SC via text or telephone, based on participant preference.
At 12 months, Index men in the experimental condition will be re-randomized to either continue receiving quarterly interactive mini-booster sessions or to stop receiving mini-boosters and return to treatment as usual.
Group II: Treatment as Usual ConditionActive Control1 Intervention
Treatment as Usual (TAU) is comprehensive and follows Department of Health and Human Services (DHHS) guidelines and local protocols on the provision of HIV primary care, which include scheduling one HIV primary care visit and lab tests (including viral load) once every six months, i.e., two HIV primary care visits per year. In addition, all sites provide standard case management and mental health and psychosocial support services to all patients.
Find a Location
Who is running the clinical trial?
University of ChicagoLead Sponsor
1,056 Previous Clinical Trials
760,009 Total Patients Enrolled
Thrive AlabamaUNKNOWN
Howard Brown HealthUNKNOWN
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I was born male and identify as a man.I am between 18 and 35 years old.I have had same-gender anal or oral sex in the last six months.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment as Usual Condition
- Group 2: Project nGage Condition
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger